Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
BackgroundPatients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS). CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality. This study aims...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.783387/full |
| _version_ | 1811311735630462976 |
|---|---|
| author | Yumin Wen Yang Xu Hui Tian Sizhu Jiang Guofang Jiang Puqing Li |
| author_facet | Yumin Wen Yang Xu Hui Tian Sizhu Jiang Guofang Jiang Puqing Li |
| author_sort | Yumin Wen |
| collection | DOAJ |
| description | BackgroundPatients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS). CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality. This study aims to examine the efficacy and safety of roxadustat in the treatment of type 4 CRAS.Methods and DesignThis study is designed as a randomized, open-label, controlled trial. A total of 68 patients diagnosed with type 4 CRAS will be randomly divided into roxadustat group and erythropoietin with a 1:1 ratio. Participants in the roxadustat group will receive roxadustat with an initial dose of 70 or 100 mg three times a week, and participants in the erythropoietin group will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a hemoglobin ranging from 100 to 120 g per liter. The primary outcome is the change in heart function, including brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF). Secondary outcomes to be assessed include death, cardiovascular events, hospitalization regarding heart failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York Heart Association (NYHA) cardiac function grade, echocardiographic parameters including left ventricular diastolic diameter and volume (LVDD and LVDV) and ventricular mass (LVM), anemia related parameters, inflammatory parameters, and safety assessments.ConclusionThe findings of this study will provide potential evidence for roxadustat in CRAS management.Trial RegistrationChinese Clinical Trial Registry, ID: ChiCTR2100050031. Registered on 16 August 2021. |
| first_indexed | 2024-04-13T10:24:05Z |
| format | Article |
| id | doaj.art-8ea500234189414e9960710bdaa50a4a |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T10:24:05Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-8ea500234189414e9960710bdaa50a4a2022-12-22T02:50:23ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-04-01910.3389/fmed.2022.783387783387Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled TrialYumin WenYang XuHui TianSizhu JiangGuofang JiangPuqing LiBackgroundPatients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS). CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality. This study aims to examine the efficacy and safety of roxadustat in the treatment of type 4 CRAS.Methods and DesignThis study is designed as a randomized, open-label, controlled trial. A total of 68 patients diagnosed with type 4 CRAS will be randomly divided into roxadustat group and erythropoietin with a 1:1 ratio. Participants in the roxadustat group will receive roxadustat with an initial dose of 70 or 100 mg three times a week, and participants in the erythropoietin group will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a hemoglobin ranging from 100 to 120 g per liter. The primary outcome is the change in heart function, including brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF). Secondary outcomes to be assessed include death, cardiovascular events, hospitalization regarding heart failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York Heart Association (NYHA) cardiac function grade, echocardiographic parameters including left ventricular diastolic diameter and volume (LVDD and LVDV) and ventricular mass (LVM), anemia related parameters, inflammatory parameters, and safety assessments.ConclusionThe findings of this study will provide potential evidence for roxadustat in CRAS management.Trial RegistrationChinese Clinical Trial Registry, ID: ChiCTR2100050031. Registered on 16 August 2021.https://www.frontiersin.org/articles/10.3389/fmed.2022.783387/fullcardiorenal-anemia syndromechronic kidney diseaseanemiaheart failureroxadustat |
| spellingShingle | Yumin Wen Yang Xu Hui Tian Sizhu Jiang Guofang Jiang Puqing Li Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial Frontiers in Medicine cardiorenal-anemia syndrome chronic kidney disease anemia heart failure roxadustat |
| title | Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial |
| title_full | Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial |
| title_fullStr | Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial |
| title_full_unstemmed | Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial |
| title_short | Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial |
| title_sort | cardiovascular protective effects of oral hypoxia inducible factor prolyl hydroxylase inhibitor roxadustat in the treatment of type 4 cardiorenal anemia syndrome protocol of a randomized controlled trial |
| topic | cardiorenal-anemia syndrome chronic kidney disease anemia heart failure roxadustat |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.783387/full |
| work_keys_str_mv | AT yuminwen cardiovascularprotectiveeffectsoforalhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatinthetreatmentoftype4cardiorenalanemiasyndromeprotocolofarandomizedcontrolledtrial AT yangxu cardiovascularprotectiveeffectsoforalhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatinthetreatmentoftype4cardiorenalanemiasyndromeprotocolofarandomizedcontrolledtrial AT huitian cardiovascularprotectiveeffectsoforalhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatinthetreatmentoftype4cardiorenalanemiasyndromeprotocolofarandomizedcontrolledtrial AT sizhujiang cardiovascularprotectiveeffectsoforalhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatinthetreatmentoftype4cardiorenalanemiasyndromeprotocolofarandomizedcontrolledtrial AT guofangjiang cardiovascularprotectiveeffectsoforalhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatinthetreatmentoftype4cardiorenalanemiasyndromeprotocolofarandomizedcontrolledtrial AT puqingli cardiovascularprotectiveeffectsoforalhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatinthetreatmentoftype4cardiorenalanemiasyndromeprotocolofarandomizedcontrolledtrial |